Table 1 |
|
|
Formulations of polypill available for prescription, and recommended indications |
|
|
Clinical history |
Intervention group |
|
|
|
|
Coronary heart disease |
Formulation 1* |
|
|
|
|
Cerebrovascular disease |
Formulation 2** |
|
|
|
|
Both or other athero-thrombotic vascular disease |
Either Formulation 1* or 2** |
|
|
|
|
>15% 5-year CVD risk, but without established CVD |
Formulation 2** |
|
|
|
|
*Polypill with aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, atenolol 50 mg **Polypill with aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg |
|
|
Liu et al. BMC Public Health 2010 10:458 doi:10.1186/1471-2458-10-458 |
|
